CVRx, Inc. (NASDAQ:CVRX) Given Average Rating of “Hold” by Analysts

Shares of CVRx, Inc. (NASDAQ:CVRX) have earned an average rating of “Hold” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $6.90.

Several equities analysts recently commented on CVRX shares. Wall Street Zen raised CVRx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of CVRx in a research report on Monday. Lake Street Capital lowered shares of CVRx from a “buy” rating to a “hold” rating and set a $3.50 price target on the stock. in a research note on Friday. Canaccord Genuity Group restated a “buy” rating and set a $10.00 price objective on shares of CVRx in a research report on Tuesday, April 14th. Finally, Craig Hallum cut shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a report on Friday.

Institutional Trading of CVRx

A number of institutional investors have recently added to or reduced their stakes in CVRX. Larson Financial Group LLC increased its position in shares of CVRx by 155.6% in the fourth quarter. Larson Financial Group LLC now owns 5,426 shares of the company’s stock valued at $39,000 after buying an additional 3,303 shares in the last quarter. R Squared Ltd purchased a new position in CVRx during the 4th quarter valued at about $74,000. Virtu Financial LLC acquired a new position in CVRx during the fourth quarter worth about $79,000. Corient Private Wealth LLC purchased a new stake in shares of CVRx in the fourth quarter valued at about $81,000. Finally, XTX Topco Ltd acquired a new stake in shares of CVRx in the fourth quarter valued at approximately $90,000. Hedge funds and other institutional investors own 75.27% of the company’s stock.

Key CVRx News

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx reported second-quarter revenue of $15.71 million, ahead of the $15.55 million analyst consensus. The company’s loss of $0.53 per share was also an improvement from the $0.57-per-share loss recorded a year earlier. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: The revenue beat suggests demand for CVRx’s neuromodulation devices remained somewhat better than expected during the quarter, potentially supporting the initial positive stock reaction. CVRx Reports Q2 Loss, Beats Revenue Estimates
• Neutral Sentiment: Management’s operating update and detailed quarterly metrics provide additional information for investors assessing procedure volumes, commercial execution and adoption of the company’s cardiovascular therapies. Compared to Estimates, CVRx Q2 Earnings: A Look at Key Metrics
• Negative Sentiment: CVRx’s $0.53-per-share loss was slightly worse than the $0.52 consensus estimate, underscoring that the company remains unprofitable. Its reported net margin was approximately negative 89%. CVRx Earnings Results
• Negative Sentiment: Management guided third-quarter revenue to $13.5 million-$14.5 million, well below the $16.9 million analyst estimate, and reduced full-year 2026 revenue guidance to $58 million-$60 million versus the $65.4 million consensus. The outlook implies slowing growth and could pressure the stock after the initial earnings reaction.

CVRx Price Performance

CVRX stock traded down $3.22 during midday trading on Friday, reaching $2.72. The stock had a trading volume of 2,057,584 shares, compared to its average volume of 331,402. CVRx has a 52-week low of $2.68 and a 52-week high of $11.30. The company has a market cap of $72.22 million, a price-to-earnings ratio of -1.34 and a beta of 0.81. The company’s fifty day simple moving average is $5.26 and its 200 day simple moving average is $6.52. The company has a current ratio of 10.20, a quick ratio of 8.89 and a debt-to-equity ratio of 2.01.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.01). CVRx had a negative return on equity of 120.76% and a negative net margin of 89.14%.The firm had revenue of $15.71 million for the quarter, compared to analyst estimates of $15.55 million. As a group, sell-side analysts predict that CVRx will post -1.89 earnings per share for the current fiscal year.

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.